- Home
- PRI vs MIRM Comparison
PRI vs MIRM Comparison
Compare PRI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRI | MIRM |
|---|---|---|
| Founded | 1927 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 7.2B |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PRI | MIRM |
|---|---|---|
| Price | $313.74 | $113.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $294.00 | $119.85 |
| AVG Volume (30 Days) | 161.2K | ★ 734.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | 67.10 | ★ 74.59 |
| EPS | ★ 5.97 | N/A |
| Revenue | ★ $3,291,713,000.00 | $19,138,000.00 |
| Revenue This Year | $3.98 | $26.22 |
| Revenue Next Year | $5.08 | $22.04 |
| P/E Ratio | $51.62 | ★ N/A |
| Revenue Growth | ★ 6.56 | N/A |
| 52 Week Low | $230.09 | $50.25 |
| 52 Week High | $317.69 | $130.00 |
Technical Indicators
Market Signals| Indicator | PRI | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 65.82 | 45.58 |
| Support Level | $255.20 | $87.93 |
| Resistance Level | $317.69 | $114.99 |
| Average True Range (ATR) | 5.55 | 5.09 |
| MACD | -0.14 | -1.87 |
| Stochastic Oscillator | 74.64 | 13.88 |
Price Performance
Historical ComparisonAbout PRI Primerica Inc.
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has three segments Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.